$ASND · Ascendis Pharma A/S
Ascendis Pharma reported Q3 FY2026 revenue of €369.7M, up 73% from €213.6M a year earlier, driven by YORVIPATH global sales (€290.6M vs €143.1M). Net profit was €74.0M versus a €61.0M loss, with diluted EPS of €1.08 versus -€1.00. Nine-month revenue reached €955.5M with net profit of €910.3M, boosted by a Rare Pediatric Disease PRV sale and a €615.0M income tax benefit. Total equity swung to €1,500.5M from a €162.8M deficit, helped by the May 2026 redemption of $575M of 2.25% convertible notes.
- Q3 revenue rose 73% YoY to €369.7M, led by YORVIPATH at €290.6M.
- Q3 net profit was €74.0M versus a €61.0M loss a year earlier.
- Nine-month net profit hit €910.3M, aided by a €615.0M income tax benefit.
- Total equity swung to €1,500.5M from a €162.8M deficit at end-2025.
- The $575M convertible note redemption in May 2026 added €719.4M to equity.
Extended-hours trading shows ASND at $267.06, up 3.00% versus the regular close, indicating a positive initial reaction to the swing to profitability.
Ascendis's first sustained commercial profitability marks a turning point for the TransCon platform's revenue story.
Ascendis's TransCon platform is now generating commercial traction, with YORVIPATH and SKYTROFA driving rare-disease revenue growth.
Revenue remains concentrated in YORVIPATH, and the nine-month profit was heavily dependent on one-time items (PRV sale and a €615.0M tax benefit).